Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus camrelizumab as second-line therapy for advanced lung cancer
ChiCTR2100047619Phase 2Recruiting
- Sponsor
- Ganyu District People's Hospital of Lianyungang City
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and camrelizumab in bronchial carcinoma, sponsored by Ganyu District People's Hospital of Lianyungang City. Primary endpoints: Adverse events and Serious adverse events. Started Jun 2021; status: recruiting.
02
Drugs
anlotinibcamrelizumab
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2100047619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047619.